The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 391 |
| Gain on change in accounting estimates on contingent royalty liability | 1,933 |
| Change in fair value of financial instruments | -359 |
| Inventory write-down for excess & obsolescence and loss on purchase commitment | 1,012 |
| Loss on contingent liability | 54 |
| Stock-based compensation | 166 |
| Depreciation | 19 |
| Amortization of intangible asset | 499 |
| Noncash interest expense | 2,366 |
| Noncash right-of-use asset amortization | 108 |
| Net loss on disposal or impairment of property and equipment | -20 |
| Gain on accounts payable and accrued expenses settlements | 5,636 |
| Trade accounts receivable | 2,648 |
| Inventories | 260 |
| Prepaid and other assets | -356 |
| Accounts payable | 182 |
| Accrued expenses and other liabilities | 4,468 |
| Accrued compensation | -907 |
| Contingent liabilities | -499 |
| Operating lease liabilities | -109 |
| Net restricted cash and cash equivalents used in operating activities | -1,992 |
| Payments related to intangible asset acquisition | 57 |
| Purchases of property and equipment | 5 |
| Net restricted cash and cash equivalents used in investing activities | -62 |
| Borrowings under short-term debt | 383 |
| Proceeds from issuance of aditxt notes related party | 2,425 |
| Payments under short-term debt and notes carried at fair value | 905 |
| Cash paid for financing costs | 12 |
| Net restricted cash and cash equivalents provided by financing activities | 1,891 |
| Net change in restricted cash and cash equivalents | -163 |
| Restricted cash and cash equivalents, beginning of period | 741 |
| Restricted cash and cash equivalents, end of period | 578 |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)